Protocol for the Osteoporosis Choice trial. A pilot randomized trial of a decision aid in primary care practice

Laurie J Pencille, Megan E Campbell, Holly K Van Houten, Nilay D Shah, Rebecca J Mullan, Brian A Swiglo, Maggie Breslin, Rebecca L Kesman, Sidna M Tulledge-Scheitel, Thomas M Jaeger, Ruth E Johnson, Gregory A Bartel, Robert A Wermers, L Joseph Melton 3rd, Victor M Montori, Laurie J Pencille, Megan E Campbell, Holly K Van Houten, Nilay D Shah, Rebecca J Mullan, Brian A Swiglo, Maggie Breslin, Rebecca L Kesman, Sidna M Tulledge-Scheitel, Thomas M Jaeger, Ruth E Johnson, Gregory A Bartel, Robert A Wermers, L Joseph Melton 3rd, Victor M Montori

Abstract

Background: Bisphosphonates can reduce fracture risk in patients with osteoporosis, but many at-risk patients do not start or adhere to these medications. The aims of this study are to: (1) preliminarily evaluate the effect of an individualized 10-year osteoporotic fracture risk calculator and decision aid (OSTEOPOROSIS CHOICE) for postmenopausal women at risk for osteoporotic fractures; and (2) assess the feasibility and validity (i.e., absence of contamination) of patient-level randomization (vs. cluster randomization) in pilot trials of decision aid efficacy.

Methods/design: This is a protocol for a parallel, 2-arm, randomized trial to compare an intervention group receiving OSTEOPOROSIS CHOICE to a control group receiving usual primary care. Postmenopausal women with bone mineral density T-scores of <-1.0, not receiving bisphosphonate therapy, and receiving care at participating primary care practices in and around Rochester, Minnesota, USA will be eligible to participate in the trial. We will measure the effect of OSTEOPOROSIS CHOICE on five outcomes: (a) patient knowledge regarding osteoporosis risk factors and treatment; (b) quality of the decision-making process for both the patient and clinician; (c) patient and clinician acceptability and satisfaction with the decision aid; (d) rate of bisphosphonate use and adherence, and (e) trial processes (e.g., ability to recruit participants, collect patient outcomes). To capture these outcomes, we will use patient and clinician surveys following each visit and video recordings of the clinical encounters. These video recordings will also allow us to determine the extent to which clinicians previously exposed to the decision aid were able to recreate elements of the decision aid with control patients (i.e., contamination). Pharmacy prescription profiles and follow-up phone interviews will assess medication start and adherence at 6 months.

Discussion: This pilot trial will provide evidence of feasibility, validity of patient randomization, and preliminary efficacy of a novel approach--decision aids--to improving medication adherence for postmenopausal women at risk of osteoporotic fractures. The results will inform the design of a larger trial that could provide more precise estimates of the efficacy of the decision aid.

Trial registration: Clinical Trials.gov Identifier: NCT00578981.

Figures

Figure 1
Figure 1
Osteoporosis Choice decision aid for a patient with a 10-year fracture risk of 20%.

References

    1. Bone Health and Osteoporosis: A Report of the Surgeon General.
    1. Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res. 2007;22:465–475. doi: 10.1359/jbmr.061113.
    1. MacLean C, Newberry S, Maglione M, McMahon M, Ranganath V, Suttorp M, Mojica W, Timmer M, Alexander A, McNamara M, Desai SB, Zhou A, Chen S, Carter J, Tringale C, Valentine D, Johnsen B, Grossman J. Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med. 2008;148:197–213.
    1. Siris ES, Harris ST, Rosen CJ, Barr CE, Arvesen JN, Abbott TA, Silverman S. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc. 2006;81:1013–1022. doi: 10.4065/81.8.1013.
    1. Weycker D, Macarios D, Edelsberg J, Oster G. Compliance with osteoporosis drug therapy and risk of fracture. Osteoporos Int. 2007;18:271–277. doi: 10.1007/s00198-006-0230-y.
    1. Rabenda V, Mertens R, Fabri V, Vanoverloop J, Sumkay F, Vannecke C, Deswaef A, Verpooten GA, Reginster JY. Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women. Osteoporos Int. 2008;19:811–818. doi: 10.1007/s00198-007-0506-x.
    1. Penning-van Beest FJ, Erkens JA, Olson M, Herings RM. Loss of treatment benefit due to low compliance with bisphosphonate therapy. Osteoporos Int. 2008;19:511–517. doi: 10.1007/s00198-007-0466-1.
    1. Cramer JA, Gold DT, Silverman SL, Lewiecki EM. A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int. 2007;18:1023–1031. doi: 10.1007/s00198-006-0322-8.
    1. Seeman E, Compston J, Adachi J, Brandi ML, Cooper C, Dawson-Hughes B, Jonsson B, Pols H, Cramer JA. Non-compliance: the Achilles' heel of anti-fracture efficacy. Osteoporos Int. 2007;18:711–719. doi: 10.1007/s00198-006-0294-8.
    1. Clinician's Guide to Prevention and Treatment of Osteoporosis.
    1. Cuddihy MT, Amadio PC, Gabriel SE, Pankratz VS, Kurland RL, Melton LJ. A prospective clinical practice intervention to improve osteoporosis management following distal forearm fracture. Osteoporos Int. 2004;15:695–700. doi: 10.1007/s00198-004-1597-2.
    1. Mauck KF, Cuddihy MT, Trousdale RT, Pond GR, Pankratz VS, Melton LJ. The decision to accept treatment for osteoporosis following hip fracture: exploring the woman's perspective using a stage-of-change model. Osteoporos Int. 2002;13:560–564. doi: 10.1007/s001980200073.
    1. Tosteson AN, Grove MR, Hammond CS, Moncur MM, Ray GT, Hebert GM, Pressman AR, Ettinger B. Early discontinuation of treatment for osteoporosis. Am J Med. 2003;115:209–216. doi: 10.1016/S0002-9343(03)00362-0.
    1. O'Connor AM, Bennett C, Stacey D, Barry MJ, Col NF, Eden KB, Entwistle V, Fiset V, Holmes-Rovner M, Khangura S, Llewellyn-Thomas H, Rovner DR. Do patient decision aids meet effectiveness criteria of the international patient decision aid standards collaboration? A systematic review and meta-analysis. Med Decis Making. 2007;27:554–574. doi: 10.1177/0272989X07307319.
    1. Weymiller AJ, Montori VM, Jones LA, Gafni A, Guyatt GH, Bryant SC, Christianson TJ, Mullan RJ, Smith SA. Helping patients with type 2 diabetes mellitus make treatment decisions: statin choice randomized trial. Arch Intern Med. 2007;167:1076–1082. doi: 10.1001/archinte.167.10.1076.
    1. U.S. Preventive Services Task Force. Screening for osteoporosis in postmenopausal women: recommendations and rationale. Ann Intern Med. 2002;137:526–528.
    1. Lewiecki EM. Review of guidelines for bone mineral density testing and treatment of osteoporosis. Curr Osteoporos Rep. 2005;3:75–83. doi: 10.1007/s11914-005-0014-x.
    1. Siris ES, Chen YT, Abbott TA, Barrett-Connor E, Miller PD, Wehren LE, Berger ML. Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Intern Med. 2004;164:1108–1112. doi: 10.1001/archinte.164.10.1108.
    1. Kanis JA, Oden A, Johnell O, Johansson H, De Laet C, Brown J, Burckhardt P, Cooper C, Christiansen C, Cummings S, Eisman JA, Fujiwara S, Glüer C, Goltzman D, Hans D, Krieg MA, La Croix A, McCloskey E, Mellstrom D, Melton LJ, Pols H, Reeve J, Sanders K, Schott AM, Silman A, Torgerson D, van Staa T, Watts NB, Yoshimura N. The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int. 2007;18:1033–1046. doi: 10.1007/s00198-007-0343-y.
    1. Watts NB, Ettinger B, LeBoff MS. FRAX facts. J Bone Miner Res. 2009;24:975–979. doi: 10.1359/jbmr.090402.
    1. Kanis JA, World Health Organization Scientific Group. Assessment of Osteoporosis at the Primary Health Care Level. Technical Report. World Health Organization Collaborating Centre for Metabolic Bone Diseases ed. Sheffield, UK: University of Sheffield; 2007.
    1. Cranney A, O'Connor AM, Jacobsen MJ, Tugwell P, Adachi JD, Ooi DS, Waldegger L, Goldstein R, Wells GA. Development and pilot testing of a decision aid for postmenopausal women with osteoporosis. Patient Educ Couns. 2002;47:245–255. doi: 10.1016/S0738-3991(01)00218-X.
    1. Montori VM, Breslin M, Maleska M, Weymiller AJ. Creating a conversation: insights from the development of a decision aid. PLoS Med. 2007;4:e233. doi: 10.1371/journal.pmed.0040233.
    1. Breslin M, Mullan RJ, Montori VM. The design of a decision aid about diabetes medications for use during the consultation with patients with type 2 diabetes. Patient Educ Couns. 2008.
    1. Wells GA, Cranney A, Peterson J, Boucher M, Shea B, Robinson V, Coyle D, Tugwell P. Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev. 2008. p. CD001155.
    1. Woo SB, Hellstein JW, Kalmar JR. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med. 2006;144:753–761.
    1. Koka S, Clarke BL, Amin S, Gertz M, Ruggiero SL. Oral bisphosphonate therapy and osteonecrosis of the jaw: what to tell the concerned patient. Int J Prosthodont. 2007;20:115–122.
    1. Mullan RJ, Montori VM, Shah ND, Christianson TJH, Bryant SC, Guyatt GH, Perestelo-Perez LI, Stroebel RJ, Yawn BP, Yapuncich V, Breslin MA, Pencille L, Smith SA. The Diabetes Mellitus Medication Choice Decision Aid: A Randomized Trial. Arch Intern Med. 2009;169:1560–1568. doi: 10.1001/archinternmed.2009.293.
    1. Jones LA, Weymiller AJ, Shah N, Bryant SC, Christianson TJ, Guyatt GH, Gafni A, Smith SA, Montori VM. Should clinicians deliver decision aids? Further exploration of the statin choice randomized trial results. Med Decis Making. 2009;29:468–474. doi: 10.1177/0272989X09333120.
    1. Fergusson D, Aaron SD, Guyatt G, Hebert P. Post-randomisation exclusions: the intention to treat principle and excluding patients from analysis. BMJ. 2002;325:652–654. doi: 10.1136/bmj.325.7365.652.
    1. Thom DH, Ribisl KM, Stewart AL, Luke DA. Further validation and reliability testing of the Trust in Physician Scale. The Stanford Trust Study Physicians. Med Care. 1999;37:510–517. doi: 10.1097/00005650-199905000-00010.
    1. O'Connor AM. Validation of a decisional conflict scale. Med Decis Making. 1995;15:25–30. doi: 10.1177/0272989X9501500105.
    1. Elwyn G, Hutchings H, Edwards A, Rapport F, Wensing M, Cheung WY, Grol R. The OPTION scale: measuring the extent that clinicians involve patients in decision-making tasks. Health Expect. 2005;8:34–42. doi: 10.1111/j.1369-7625.2004.00311.x.
    1. Nannenga MR, Montori VM, Weymiller AJ, Smith SA, Christianson TJ, Bryant SC, Gafni A, Charles C, Mullan RJ, Jones LA, Bolona ER, Guyatt GH. A treatment decision aid may increase patient trust in the diabetes specialist. The Statin Choice randomized trial. Health Expect. 2009;12:38–44. doi: 10.1111/j.1369-7625.2008.00521.x.
    1. Haynes RB, McDonald HP, Garg AX. Helping patients follow prescribed treatment: clinical applications. Jama. 2002;288:2880–2883. doi: 10.1001/jama.288.22.2880.
    1. Stephenson BJ, Rowe BH, Haynes RB, Macharia WM, Leon G. The rational clinical examination. Is this patient taking the treatment as prescribed? JAMA. 1993;269:2779–2781. doi: 10.1001/jama.269.21.2779.
    1. Karve S, Cleves MA, Helm M, Hudson TJ, West DS, Martin BC. An empirical basis for standardizing adherence measures derived from administrative claims data among diabetic patients. Med Care. 2008;46:1125–1133. doi: 10.1097/MLR.0b013e31817924d2.
    1. Hess LM, Raebel MA, Conner DA, Malone DC. Measurement of adherence in pharmacy administrative databases: a proposal for standard definitions and preferred measures. Ann Pharmacother. 2006;40:1280–1288. doi: 10.1345/aph.1H018.
    1. Montori VM, Guyatt GH. Intention-to-treat principle. CMAJ. 2001;165:1339–1341.
    1. Abadie R, Weymiller AJ, Tilburt J, Shah N, Charles C, Gafni A, Montori V. Clinician's use of the Statin Choice decision aid in patients with diabetes: a videographic study nested in a randomized trial. J Eval Clin Pract. 2009;15(3):492–7. doi: 10.1111/j.1365-2753.2008.01048.x.
    1. Elwyn G, Legare F, Weijden T, Edwards A, May C. Arduous implementation: Does the Normalisation Process Model explain why it's so difficult to embed decision support technologies for patients in routine clinical practice. Implement Sci. 2008;3:57. doi: 10.1186/1748-5908-3-57.
    1. May CR, Mair F, Finch T, Macfarlane A, Dowrick C, Treweek S, Rapley T, Ballini L, Ong BN, Rogers A, Murray E, Elwyn G, Légaré F, Gunn J, Montori VM. Development of a theory of implementation and integration: Normalization Process Theory. Implement Sci. 2009;4:29. doi: 10.1186/1748-5908-4-29.

Source: PubMed

3
Subscribe